| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/23/2009 | US20090186102 Herbal medicine for osteoporosis and related conditions |
| 07/23/2009 | US20090186030 Antibodies that bind both bcma and taci |
| 07/23/2009 | US20090186010 Methods for the identification of ikkalfa function and other genes useful for treatment of inflammatory diseases |
| 07/23/2009 | US20090186002 rAAV-delivered alpha-1-antitrypsin compositions and method for the treatment and prevention of diabetes |
| 07/23/2009 | DE19521753B4 Monomere Insulinanalogonformulierungen Monomeric insulin analog formulations |
| 07/23/2009 | DE102007054497B3 New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy- phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy- hexyl)-amide useful e.g. to treat hyperlipidemia |
| 07/23/2009 | CA2712948A1 Phenylacetamide derivative |
| 07/23/2009 | CA2712614A1 Combination therapy comprising sglt inhibitors and dpp4 inhibitors |
| 07/23/2009 | CA2712404A1 Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| 07/23/2009 | CA2712245A1 Crystalline (r)-2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| 07/23/2009 | CA2711931A1 Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological applications thereof |
| 07/23/2009 | CA2710815A1 Combination of metformin and an mtp inhibitor |
| 07/22/2009 | EP2080525A1 Remodeling and Glycoconjugation of Peptides |
| 07/22/2009 | EP2080521A1 Gastrin compositions and formulations, and methods of use and preparation |
| 07/22/2009 | EP2079747A1 Heterocyclic compounds useful as anabolic agents for livestock animals |
| 07/22/2009 | EP2079728A1 N-aryl pyrazole compounds for use against diabetes |
| 07/22/2009 | EP2079703A1 Indazole derivatives useful as l-cpt1 inhibitors |
| 07/22/2009 | EP2079701A1 Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators |
| 07/22/2009 | EP2079688A1 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 07/22/2009 | EP2079525A1 Calcium receptor modulating agents |
| 07/22/2009 | EP2079476A2 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| 07/22/2009 | EP2079471A2 Food extracts containing n-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders |
| 07/22/2009 | EP2079468A1 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 07/22/2009 | EP2079307A2 Farnesoid x receptor agonists |
| 07/22/2009 | EP2006286A9 Isoxazole derivative and isothiazole derivative having inhibitory activity on 11 beta -hydroxysteroid dehydrogenase type i |
| 07/22/2009 | EP1989192B1 1,3-dioxane carboxylic acids |
| 07/22/2009 | EP1896460B1 Benzofuranyl derivatives as 5-ht6-receptor inhibitors |
| 07/22/2009 | EP1734986A4 Method for modulating appetite |
| 07/22/2009 | EP1667964B1 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 07/22/2009 | EP1663395B1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 07/22/2009 | EP1625112B1 Novel compounds for treatment of obesity |
| 07/22/2009 | EP1492761B1 Amino acids with affinity for the alpha-2-delta-protein |
| 07/22/2009 | EP1392680B1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| 07/22/2009 | EP1392337B2 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
| 07/22/2009 | EP1133517B1 INTRANUCLEAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 07/22/2009 | CN101486682A N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 07/22/2009 | CN101486679A 5HT2c receptor modulators |
| 07/22/2009 | CN101486678A 5HT2C receptor modulators |
| 07/22/2009 | CN101486677A 5HT2c receptor modulators |
| 07/22/2009 | CN101485664A 5HT2c receptor modulators |
| 07/22/2009 | CN100516062C New medicine |
| 07/22/2009 | CN100516041C Novel heteroaryl derivative |
| 07/22/2009 | CN100516037C Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 07/22/2009 | CN100516024C Amino-propanol derivatives |
| 07/22/2009 | CN100515491C Medical use of interleukin-22 |
| 07/22/2009 | CN100515446C Nontoxic, non-anaphylactoid edible versatile nutriment as drug and cosmetic for beauty treatment and blacking hair and preparation method |
| 07/22/2009 | CN100515427C self emulsifying soft capsule of breviscapine and its preparation |
| 07/21/2009 | USRE40861 4-Trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate; hypoglycemic agents; antidiabetic agents; antiischemic agents; congestive heart failure; obesity |
| 07/21/2009 | US7563909 Nitrate derivatives of atorvastatin with improved pharmacological activity and enhanced tolerability; coronary syndromes, neurodegenerative disorders, and for reducing cholesterol levels; antiinflammatory, antithrombotic and antiplatelet activity; fluvastatin 4-(nitrooxy)butyl ester |
| 07/21/2009 | US7563884 Antisense modulation of PTP1B expression |
| 07/21/2009 | US7563822 active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion |
| 07/21/2009 | US7563790 Pyridazine derivatives |
| 07/21/2009 | US7563778 Antisense oligonucleotide preparation method |
| 07/21/2009 | CA2495943C Indoles having anti-diabetic activity |
| 07/21/2009 | CA2470809C 6-amino-morphinan derivatives, method of manufacturing them and their application |
| 07/21/2009 | CA2404548C 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses |
| 07/21/2009 | CA2387486C Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/21/2009 | CA2379972C Prodrug of an ice inhibitor |
| 07/21/2009 | CA2348988C Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor |
| 07/18/2009 | CA2650135A1 Process for obtaining dried plant material |
| 07/16/2009 | WO2009089545A1 Synthetic triterpenoids and methods of use in the treatment of disease |
| 07/16/2009 | WO2009089448A1 Therapeutic disulfide compounds for treating pain and diabetes |
| 07/16/2009 | WO2009089107A1 Dietary compositions for promoting weight loss |
| 07/16/2009 | WO2009089093A1 Thyroid hormone receptor agonists |
| 07/16/2009 | WO2009088997A1 Lactam inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 07/16/2009 | WO2009088738A2 Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
| 07/16/2009 | WO2009087988A1 Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy |
| 07/16/2009 | WO2009087987A1 Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly |
| 07/16/2009 | WO2009087938A1 Capsule formulation |
| 07/16/2009 | WO2009087395A1 Weight reducing compounds |
| 07/16/2009 | WO2009087285A1 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof |
| 07/16/2009 | WO2009087263A1 Composition for improving liver metabolism and diagnostic method |
| 07/16/2009 | WO2009087238A2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies |
| 07/16/2009 | WO2009086685A1 An alginic acid with low molecular weight, its salts, uses, preparative methods, pharmaceutical compositions and foods |
| 07/16/2009 | WO2009086592A1 Method of increasing metabolism |
| 07/16/2009 | WO2009049105A3 Methods for inducing satiation |
| 07/16/2009 | WO2009046860A3 Use of dago as a therapeutic agent |
| 07/16/2009 | WO2009046859A3 Use of af12198 and dago as therapeutic agents |
| 07/16/2009 | WO2009046015A3 Combination therapies for treating type 1 diabetes |
| 07/16/2009 | WO2009045291A3 Mast cell stabilizers in the treatment of obesity |
| 07/16/2009 | WO2009040035A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2009039990A3 Use of icam peptide as a therapeutic agent |
| 07/16/2009 | WO2009039974A3 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/16/2009 | WO2009033817A3 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 07/16/2009 | WO2009033766A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2008147562A3 Dietary formulations and methods for treatment of inflammation and other disorders |
| 07/16/2009 | WO2008115055A3 Rhodospirillum and phaeospirillum in animal feed for the purpose of obtaining food products with a reduced cholesterol level |
| 07/16/2009 | WO2005011680A8 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 07/16/2009 | US20090182056 Pharmaceutical formulations of amyloid inhibiting compounds |
| 07/16/2009 | US20090182053 Fenofibric acid amorphous dispersion; method of making; and method of use thereof |
| 07/16/2009 | US20090182049 Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans |
| 07/16/2009 | US20090182047 Utilization of dialkylfumarates |
| 07/16/2009 | US20090182045 Use of aminaphtone for the preparation of a medicament for treating arteriopathies |
| 07/16/2009 | US20090182044 Nitrate amino acid chelates |
| 07/16/2009 | US20090182037 Cognitive Function |
| 07/16/2009 | US20090182032 Companion animal compositions including lipoic acid and methods of use thereof |
| 07/16/2009 | US20090182030 Process for the preparation of amorphous calcium salt of atorvastatin |
| 07/16/2009 | US20090182007 Organic compounds |
| 07/16/2009 | US20090181994 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| 07/16/2009 | US20090181989 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer |